Evercore Downgrades Intellia (NTLA) Despite Strong ATTR Trial Data [Yahoo! Finance]
Evercore Inc. Class A (EVR)
Last evercore inc. class a earnings: 4/22 06:00 am
Check Earnings Report
US:NYSE Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=66653&p=irol-irhome
Company Research
Source: Yahoo! Finance
11, Evercore ISI downgraded Intellia Therapeutics (NASDAQ:NTLA) from Outperform to In Line and cut its price target to $8 from $17, citing uncertainty around the company's ATTR program timeline. While acknowledging promising efficacy updates, the firm noted that clarity on development milestones remains lacking, narrowing the path to value. Evercore Downgrades Intellia (NTLA) Despite Strong ATTR Trial Data Source: Pexels The downgrade followed Intellia's November 10 announcement of three-year follow-up data from its Phase 1 trial of nexiguran ziclumeran (nex-z) in transthyretin (ATTR) amyloidosis with cardiomyopathy. Results showed an 87% mean serum TTR reduction at 36 months with no waning effect, alongside stabilization or improvement in key biomarkers and functional status. Mortality rates were also significantly lower compared to a matched cohort, underscoring the therapy's potential impact. CEO John Leonard highlighted the durability of benefit even in advanced heart fail
Show less
Read more
Impact Snapshot
Event Time:
EVR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVR alerts
High impacting Evercore Inc. Class A news events
Weekly update
A roundup of the hottest topics
EVR
News
- Meta cutting its Metaverse plans makes a lot of sense, says Evercore's Mark Mahaney [CNBC]CNBC
- Ashish Varshneya Joins Evercore as Senior Managing Director in the Healthcare Investment Banking GroupBusiness Wire
- Repligen Corporation (RGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Buy these consumer stocks that may get a boost from a Fed rate cut, says Evercore ISI [CNBC]CNBC
- Don't expect next interest rate cut to be preemptive, says Evercore ISI's Guha [CNBC]CNBC
EVR
Earnings
- 10/29/25 - Beat
EVR
Sec Filings
- 11/12/25 - Form SCHEDULE
- 11/10/25 - Form 4
- 11/7/25 - Form 144
- EVR's page on the SEC website